UK Medical Device Regulatory Consulting

Expert UKCA Compliance Support and MHRA Regulatory Guidance for Medical Devices and Diagnostics

Following the UK's departure from the European Union, the regulatory landscape for medical devices and in vitro diagnostics (IVDs) in Great Britain has diverged from EU rules. Manufacturers must now comply with the UK Medical Devices Regulations 2002 (as amended), secure UK Conformity Assessed (UKCA) marking, and engage directly with the Medicines and Healthcare products Regulatory Agency (MHRA). ProPharma’s team of medical device experts provides regulatory consulting services to support medical device and IVD companies seeking UK market access, compliance, and lifecycle support.

Our team includes former MHRA officials and seasoned UK regulatory professionals who guide clients through every stage of the UKCA process—ensuring efficient market entry and sustained regulatory compliance.

Partner With Us

Comprehensive Regulatory Consulting Solutions for Medical Devices, Diagnostics, and Combination Products in the UK

Pin leading to another pin icon

Regulatory Strategy

Regulatory Strategy

authority-meetings

Regulatory Meetings

Regulatory Meetings

Submissions

Regulatory Submissions

Regulatory Submissions

medtech-devices

Preclinical Testing

Preclinical Testing

Global submission icon

Market Access

Market Access

signal-management

Postmarket Surveillance

Postmarket Surveillance

UK Regulatory Strategy and UKCA Marking Support

Developing a country-specific regulatory strategy is critical to success in the UK market. ProPharma works with manufacturers to build clear, tailored roadmaps aligned with the UK MDR, classification rules, and MHRA expectations. Whether you're launching a new product in Great Britain or transitioning from CE marking to UKCA, we help define the appropriate route to market and ensure your submission and supporting documentation meet all current regulatory requirements.

Our UKCA regulatory strategy services include:

  • Classification and regulatory pathway assessment
  • Gap analysis of CE-marked products for UKCA compliance
  • Strategic planning for legacy product transition and new product launch
  • Integration of applicable UK standards and MHRA guidance
  • Coordination of parallel EU and UK regulatory strategies (where applicable)
Business Man Presenting at Meeting

MHRA Regulatory Meetings and Correspondence Support

Early and proactive engagement with the MHRA can clarify regulatory expectations, especially for novel or borderline products, devices requiring clinical investigation, or those undergoing significant change. Our team assists clients in preparing for regulatory meetings and formal communications with MHRA to support classification queries, innovation advice, and clinical investigation applications.

Our MHRA support services include:

  • Preparation of meeting requests and briefing packages
  • Strategy development for regulatory question framing
  • Support for responses to MHRA information requests
  • Clinical investigation consultation and submission assistance
  • UK Responsible Person (UKRP) liaison services
business-executives-shaking-hands-across-table-as-208777699

UKCA Regulatory Submissions and Approved Body Engagement

Our team of regulatory consultants partners with clients to prepare and manage regulatory submissions for UKCA marking across all device and diagnostic classifications. For higher-risk devices, we provide full support with UK Approved Body submissions, technical documentation, and conformity assessments.

Our UKCA submission services include:

  • Preparation of UKCA-compliant technical files and documentation
  • Development and review of Clinical Evaluation Reports (CERs) and Performance Evaluation Reports (PERs)
  • Labeling and IFU compliance with UK requirements
  • Declaration of Conformity and UKCA certificate support
  • UKRP documentation preparation and coordination
  • Responses to Approved Body queries or MHRA requests

Whether your product is Class I and self-declared or requires third-party review, we ensure your UKCA submission is thorough, accurate, and ready for review.

Woman typing on computer keyboard

Preclinical and Biocompatibility Testing for the UK Market

UK regulators expect robust preclinical evidence for medical devices and diagnostics entering the market. Our team helps manufacturers plan, execute, and interpret testing strategies that align with UK requirements and internationally recognized standards.

Our testing strategy support includes:

  • Biocompatibility planning (ISO 10993)
  • Electrical safety and EMC testing (IEC 60601)
  • Software validation (IEC 62304) and cybersecurity
  • Usability and human factors (IEC 62366)
  • Performance testing and design verification
  • Risk management integration (ISO 14971)

We ensure that your nonclinical evidence meets MHRA expectations and supports successful UKCA marking.

Gloved hands holding vials near a keyboard and computer monitor in a dark setting

UK Market Access and Reimbursement Strategy

Unlike the centralized EMA model, the UK operates its own health technology assessment and reimbursement systems. ProPharma helps manufacturers navigate the NHS procurement process, prepare for NICE reviews, and explore early access opportunities.

Our UK market access services include:

  • Reimbursement strategy development for NHS adoption
  • NICE Scientific Advice and evidence generation planning
  • Support for NICE Medical Technologies Evaluation Program (MTEP)
  • Value proposition development and health economic modeling
  • Early access and accelerated access program guidance

We help ensure that your UK regulatory strategy aligns with reimbursement requirements to support successful commercialization.

Row of United Kingdom flags hanging

Postmarket Surveillance and UK Regulatory Compliance

Postmarket obligations under the UK MDR mirror many of the EU requirements but are managed independently by MHRA. Our team provides full support for postmarket surveillance, vigilance, and ongoing compliance in the UK, including:

  • PMS Plan and report development
  • Periodic Safety Update Report (PSUR) creation
  • Clinical and performance follow-up (PMCF/PMPF)
  • Vigilance reporting and <abbr title="Field Safety Corrective Action reports ">FSCA</abbr> management to MHRA
  • Audit readiness and CAPA support
  • Regulatory intelligence for UK-specific updates and deadlines

We help manufacturers maintain UKCA certification, manage risk, and stay fully compliant with UK regulatory obligations.

Row of professionals working at a conference table

UKCA ready? We are.

Partner with ProPharma to simplify MHRA submissions, achieve UKCA compliance, and accelerate market access.

Speak with a UK Regulatory Expert

Your Trusted Partner for UKCA Regulatory Success

The UK’s evolving regulatory framework presents both challenges and strategic opportunities for medical device and IVD manufacturers. From changing timelines for UKCA implementation to shifting MHRA guidance and requirements for UK Responsible Persons, staying compliant requires not only technical know-how but also agile strategic planning.

At ProPharma, we bring together deep regulatory expertise, former MHRA leadership experience, and hands-on operational support to help manufacturers confidently navigate the UK medical device approval process. Whether you're entering the UK market for the first time, transitioning from CE to UKCA marking, or seeking to maintain postmarket compliance, our consultants serve as an extension of your internal team—anticipating regulatory changes, reducing risk, and accelerating timelines.

Our team of regulatory affairs and medical device experts delivers:

  • Strategic foresight to align product development with UK MDR and MHRA expectations
  • Hands-on support for technical file preparation, clinical evaluation, and regulatory submissions
  • Experienced guidance through MHRA interactions, UKRP coordination, and Approved Body engagement
  • Integrated lifecycle services that span premarket strategy, market access planning, and postmarket compliance
  • A tailored approach for every client—startups, SMEs, and global leaders alike

As the UK continues to define its post-Brexit regulatory identity, ProPharma remains a steady, informed partner who helps you make smart, compliant, and commercially sound decisions every step of the way.

ProPharma: The World's Leading Regulatory Consultancy

Ready to bring your device to the UK market—or ensure continued compliance? Contact us today to speak with a UK regulatory expert and discover how we can support your success in the British medical device landscape.

Speak with an Expert

News & Insights

Thought Leadership Webinars Press Awards Resource Library
Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guide for Marketing Authorization Holders (MAHs)

July 25, 2025

Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guid...

Learn about the crucial roles of QPPV, LPPV, and PSMF in ensuring effective pharmacovigilance and regulatory compliance for Marketing Authorization Holders (MAHs).

Read Full Article
FDA Publishes over 200 Complete Response Letters (CRLs)

July 24, 2025

FDA Publishes over 200 Complete Response Letters (CRLs)

FDA's new transparency with over 200 CRLs empowers sponsors to navigate regulatory challenges more effectively, accelerating drug approvals and enhancing patient access to treatments.

Read Full Article
Navigating EMA and Global Regulations for Medical Information Services

July 24, 2025

Navigating EMA and Global Regulations for Medical Information Services

ProPharma guides clients through global medical information regulatory landscapes, ensuring compliance and excellence across markets with tailored solutions, AI integration, and continuous training.

Read Full Article
View all Thought Leadership
ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Read Full Article
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

Read Full Article
ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

Read Full Article
View all Press
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

Read Full Article
ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

Read Full Article
ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Read Full Article
View all Awards
Case Study From Drafts to First Patient in Record Time - ProPharma

July 8, 2025

From Drafts to First Patient in Record Time

Launching a global clinical study from draft documents, the team achieved US first patient in in 3.5 months and met ambitious global submission timelines. Strong collaboration, proactive planning,...

Read Full Article
Whitepapers FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submission

June 23, 2025

FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submiss...

A Strategic Guide to Early FDA Engagement for a Streamlined NDA Pathway For drug developers leveraging the 505(b)(2) NDA pathway, early engagement with FDA is a critical determinant of regulatory...

Read Full Article
Case Study Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina - ProPharma

June 18, 2025

Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina

Acting as Marketing Authorization Holder in Bosnia and Herzegovina, Clinres—a ProPharma company—helped a global pharma client overcome regulatory delays, misaligned planning, and seasonal launch...

Read Full Article
View all Resources
Avoiding Common Pitfalls During FDA Inspections

July 29, 2025

Avoiding Common Pitfalls During FDA Inspections

Starting August 2025, the FDA will conduct unannounced inspections at non-U.S. sites. This webinar explores common inspection pitfalls and how to maintain global inspection readiness with expert...

Register
Inside FDA Review: Crafting a Quality ANDA Labeling Submission

July 22, 2025

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

Gain rare, insider insight into the FDA’s expectations for ANDA submissions in this session led by Marshall Florence, PharmD, a former FDA reviewer who recently joined our team. With firsthand...

Watch the Replay
MAH Essentials: Ensuring Compliance for European Market Entry

July 10, 2025

MAH Essentials: Ensuring Compliance for European Market Entry

This webinar covers the key responsibilities of Marketing Authorization Applicants/Holders and Qualified Persons in the EEA/UK, including pharmacovigilance requirements, legal entity setup, and...

Watch the Replay
View all Webinars

News & Insights

Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guide for Marketing Authorization Holders (MAHs)

July 25, 2025

Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guid...

Learn about the crucial roles of QPPV, LPPV, and PSMF in ensuring effective pharmacovigilance and regulatory compliance for Marketing Authorization Holders (MAHs).

FDA Publishes over 200 Complete Response Letters (CRLs)

July 24, 2025

FDA Publishes over 200 Complete Response Letters (CRLs)

FDA's new transparency with over 200 CRLs empowers sponsors to navigate regulatory challenges more effectively, accelerating drug approvals and enhancing patient access to treatments.

Navigating EMA and Global Regulations for Medical Information Services

July 24, 2025

Navigating EMA and Global Regulations for Medical Information Services

ProPharma guides clients through global medical information regulatory landscapes, ensuring compliance and excellence across markets with tailored solutions, AI integration, and continuous training.

Previous Post Arrow Next Post Arrow
ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study From Drafts to First Patient in Record Time - ProPharma

July 8, 2025

From Drafts to First Patient in Record Time

Launching a global clinical study from draft documents, the team achieved US first patient in in 3.5 months and met ambitious global submission timelines. Strong collaboration, proactive planning,...

Whitepapers FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submission

June 23, 2025

FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submiss...

A Strategic Guide to Early FDA Engagement for a Streamlined NDA Pathway For drug developers leveraging the 505(b)(2) NDA pathway, early engagement with FDA is a critical determinant of regulatory...

Case Study Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina - ProPharma

June 18, 2025

Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina

Acting as Marketing Authorization Holder in Bosnia and Herzegovina, Clinres—a ProPharma company—helped a global pharma client overcome regulatory delays, misaligned planning, and seasonal launch...

Previous Resource Arrow Next Resource Arrow
Avoiding Common Pitfalls During FDA Inspections

July 29, 2025

Avoiding Common Pitfalls During FDA Inspections

Starting August 2025, the FDA will conduct unannounced inspections at non-U.S. sites. This webinar explores common inspection pitfalls and how to maintain global inspection readiness with expert...

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

July 22, 2025

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

Gain rare, insider insight into the FDA’s expectations for ANDA submissions in this session led by Marshall Florence, PharmD, a former FDA reviewer who recently joined our team. With firsthand...

MAH Essentials: Ensuring Compliance for European Market Entry

July 10, 2025

MAH Essentials: Ensuring Compliance for European Market Entry

This webinar covers the key responsibilities of Marketing Authorization Applicants/Holders and Qualified Persons in the EEA/UK, including pharmacovigilance requirements, legal entity setup, and...

Previous Webinar Arrow Next Webinar Arrow